<DOC>
	<DOCNO>NCT02033018</DOCNO>
	<brief_summary>The purpose study evaluate clinical result anti-VEGF intra-vitreal injection ( IVT ) CNV secondary</brief_summary>
	<brief_title>Aflibercept Intravitreal Injection Myopic Choroidal Neovascularization</brief_title>
	<detailed_description>Twenty consecutive patient ( 30 eye ) subfoveal PM-CNV , 9 unsuccessfully treat Visudyne PDT , treat IVT 0.5mg ranibizumab . ETDRS best correct visual acuity , macular thickness OCT scan , angiographic feature record evaluate . The aspect OCT scan pass across PM-CNV also analyze . IVTs repeat case persistent angiographic leakage OCT scan show retinal thickening edema serous retinal detachment . The follow-up period least 6 month</detailed_description>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Retinal Neovascularization</mesh_term>
	<criteria>Myopic CNVM Patients poor compliance Patients uncontrolled diabetes hypertension medical condition increase risk complication like recent history Stroke myocardial infraction ( &lt; one year ) . ( Physician clearance obtain patient ) . Age relate macular degeneration Juxtafoveal Subfoveal CNVM : Recurrent CNVM follow PDT TTT IVTA . Patient could afford PDT , Macugen Lucentis FDA approve . Patients undergone major surgery 28 day , exclude study also suspend prior elective surgery . Refractory macular oedema due vein occlusion , Pseudophakia , Clinically significant macular oedema ( CSME ) etc . affect vision respond adequately usual treatment method . Proliferative diabetic retinopathy , nonresolving vitreous haemorrhage PDR . Idiopathic CNVM , Inflammatory CNVM condition associate CNVM .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Aflibercept</keyword>
	<keyword>Myopia</keyword>
	<keyword>Complications</keyword>
	<keyword>Neovascularization</keyword>
	<keyword>OCT</keyword>
</DOC>